Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep:114:203-214.
doi: 10.1016/j.semcancer.2025.07.002. Epub 2025 Jul 8.

The impact of sarcopenic obesity on cancer clinical outcomes

Affiliations
Review

The impact of sarcopenic obesity on cancer clinical outcomes

Bahadır Köylü et al. Semin Cancer Biol. 2025 Sep.

Abstract

Sarcopenic obesity is a distinct clinical condition characterized by the coexistence of excess fat and reduced muscle mass. Although the prevalence of sarcopenic obesity varies depending on the definition used, it is increasingly recognized as a significant health concern, regardless of age and underlying disease. Despite limited understanding of the crosstalk between sarcopenic obesity and cancer, emerging evidence suggests that sarcopenic obesity not only promotes a metabolic and inflammatory environment conducive to cancer progression but also profoundly impacts treatment efficacy, safety, and survival outcomes. This review provides a concise overview of the key aspects of sarcopenic obesity, with a particular focus on its role in the cancer setting. We also assess existing evidence on its influence on oncological outcomes in both early and advanced stages of the various solid tumor types.

Keywords: Cancer; Obesity; Sarcopenia; Sarcopenic obesity.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Bahadır Köylü has nothing to declare. Cem Sulu has nothing to declare. Volkan Yumuk has engaged in advisory boards and lectures with Novo Nordisk, Eli Lilly, Rhythm, and Regeneron. Fulden Yumuk has engaged in advisory boards of Bayer, Amgen, Astra Zeneca, and Bristol-Myers Squibb, and in clinical trials of Amgen and Astra Zeneca.

LinkOut - more resources